The coverage by Cigna Healthcare expands access to the procedure, when clinically appropriate, to patients in all 50 states as well as Washington D.C. and Puerto Rico.
Funds will be used to scale engineering, obtain regulatory clearances and globally commercialize across multiple specialties including orthopedic surgery.
The device features a proprietary wave-like design that provides strength, porosity and stability, with a large implant graft aperture for bone graft material.
The company's proprietary protein-engineering platform produces targeted therapeutics that can coat implants and devices to achieve hyper-local delivery over long time periods.
Pooled 3-year outcomes from Intracept procedures demonstrate long-term pain relief and reduced opioid use in chronic vertebrogenic low back pain patients.